Geneticure, a US-based precision medicine company developing genetic tests to guide hypertension treatment, has received a $1 million investment from Xcellerant Ventures through the venture capital firm’s Fund I. The investment was announced on October 21, 2026.
The funding will support Geneticure’s commercial expansion, the establishment of a new clinical laboratory in Arizona, and further clinical validation of its testing technology. The company also plans to develop its reimbursement strategy and strengthen commercial readiness ahead of a planned Series A financing round.
Founded in 2014 by Scott Snyder, Eric Snyder, Ryan Sprissler and Thomas Olson, Geneticure operates in Rochester, Minnesota, and Tucson, Arizona. Scott Snyder serves as CEO.
Geneticure develops genetic testing technologies intended to help healthcare providers select hypertension treatments based on individual patient characteristics. Its non-invasive cheek-swab testing platform analyzes genetic information associated with physiological pathways involved in blood pressure regulation.
The company is developing a test designed to predict whether patients with resistant hypertension are likely to respond to renal denervation, a procedure used to treat high blood pressure. The proposed test aims to help physicians identify suitable candidates before treatment.
Geneticure also offers a commercial genetic test that provides guidance on hypertension medication selection. According to Xcellerant Ventures, the company holds four US patents related to its precision medicine technology.
Xcellerant Ventures is a Scottsdale, Arizona-based venture capital firm focused on early-stage healthcare technology businesses. Its investment in Geneticure will support the company’s planned laboratory expansion and continued development of its hypertension treatment-selection technologies.
